Table 3.
Treatment regimens and response rates in ATLL patients
| Therapy | Number | Overall Response Rate, % (n) |
|---|---|---|
| First-line Therapy (N=87) | ||
| DA-EPOCH | 37 | 81.5 (22/27, CR, 15; PR, 7) |
| CHOEP | 10 | 77.8 (7/9, CR, 1; PR, 6) |
| CHOP | 24 | 45.0 (9/20, CR, 2; PR, 7) |
| CEOP | 2 | 50.0 (1/2, PR, 1) |
| CHP+BV | 1 | 100 (1/1, CR, 1) |
| COP | 2 | N |
| CP | 2 | N/SD |
| CP+Hyper-CVAD | 1 | N |
| EDOCP | 1 | PD |
| VCAP | 1 | PD |
| VDCLP | 2 | PD |
| VDCP | 1 | 100 (1/1, CR, 1) |
| VEPD | 1 | N |
| VICLP | 1 | N |
| Chidamide+gemcitabine | 1 | N |
| Second-line Therapy (N=27) | ||
| DA-EDOCH | 12 | 25.0 (3/12, CR, 3) |
| CHOEP | 1 | PD |
| Chidamide+vinorelbine+gemcitabine | 1 | PD |
| P-Gemox | 1 | N |
| Interferon | 1 | SD |
| Chidamide+COP | 1 | PD |
| Chidamide+GDP | 2 | PD |
| Chidamide+pred+CAG | 1 | N |
| Chidamide+Gemox4 | 1 | PR |
| Azacitidine+GHA | 2 | SD/N |
| VICLP | 1 | PD |
| IMRT | 1 | SD |
| Chidamide | 1 | PD |
| Chidamide+venetoclax+Gemox | 1 | N |
CR, complete response; PR, partial response; SD, Stable disease; N, not assessable; DA-EPOCH, dose-adjusted etoposide, cyclophosphamide, vincristine, doxorubicin, and prednisone; CHOEP, cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone; CEOP, cyclophosphamide, etoposide, vincristine, prednisone; CHOP, cyclophosphamide, vincristine, doxorubicin, and prednisone; CHP+BV, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone; Hyper-CVAD, cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine; GDP, gemcitabine, dexamethasone, and cisplatin; VDCLP, vincristine, daunomycin, cyclophosphamide, asparaginase, and dexamethasone; IMRT, radiotherapy; PD, progression of disease; VCAP, vincristine, cyclophosphamide, doxorubicin and prednisone; P-Gemox, pegaspargase, Gemcitabine, and oxaliplatin.